IKNA Profile
Ikena Oncology, Inc. is a biopharmaceutical company specializing in the development of targeted therapies for oncology, with a focus on addressing specific unmet medical needs through biomarker-driven approaches. The company's strategy involves creating precision medicines that cater to distinct patient populations based on their unique biomarker profiles, aiming to improve treatment outcomes for various cancer types.
Ikena's leading product candidate, IK-930, is an oral small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, which plays a critical role in the Hippo signaling pathway. This pathway is implicated in various cancers, and IK-930 aims to disrupt its activity to target tumor growth. The company's pipeline also includes a small molecule inhibitor program targeting ERK5, a key component in the RAS signaling pathway, which is frequently altered in cancer.
Additionally, Ikena is advancing IK-175, an oral inhibitor targeting the aryl hydrocarbon receptor (AhR), which is involved in cancer progression and immune modulation. Another notable candidate, IK-007, is an oral selective antagonist of the EP4 receptor, which the company is developing for the treatment of microsatellite stable colorectal cancer. These innovative approaches are designed to address critical gaps in current cancer therapies and offer new treatment options for patients.
Founded in 2016 and headquartered in Boston, Massachusetts, Ikena Oncology is committed to advancing its portfolio of targeted oncology therapies. The company's research and development efforts are focused on leveraging cutting-edge science to develop novel treatments that can more effectively address the complexities of cancer and improve patient outcomes.
|
